Sphingolipid signalling was found to be one of the key mediators in the pro-inflammatory mechanisms of IBD since over-expressed SphK1 and high concentrations of S1P in plasma, lymphocytes of patients with gastrointestinal cancer (Degagné and Saba, 2014; Sukocheva et al., 2020b). The gene discussed is SPHK1; the disease is inflammatory bowel disease.